Sanofi's trimmed on­col­o­gy plans lead to $3B biobucks dent for IGM

Sanofi’s on­col­o­gy prun­ing will lead to the evap­o­ra­tion of an es­ti­mat­ed $3 bil­lion in po­ten­tial biobucks for part­ner IGM Bio­sciences.

The French phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER